ESMO 2023: Pre- and Postsurgical Immunotherapy for Resectable Early-Stage NSCLC
Posted: 11/01/2023 | By: Sarah Campen, PharmD

Results from CheckMate 77T—a placebo-controlled, randomized, double-blind, phase III study evaluating neoadjuvant nivolumab plus chemotherapy followed by surgery and adjuvant nivolumab in patients with resectable stage II to IIIB NSCLC—were presented at the ESMO Congress 2023 (Abstract LBA1).

Question 1 of 5

What percentage of patients diagnosed with non–small cell lung cancer have operable disease?

Choose 1